Fatemeh Shirafkan
Research Subjects
Fatemeh Shirafkan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ali Akbar Moghadamnia
Pharmaceutical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
1 shared publication - Anahita Ebrahimpour
Cellular and Molecular Biology Research Center
1 shared publication - Bhargavi Sundaresan
Institute of Pharmacology, Biochemical Pharmacological Center, University of Marburg, 35043 Marburg, Germany
1 shared publication - Fateme Madani
Student Research Committee
1 shared publication - Kevin Ripperger
Institute of Pharmacology, Biochemical Pharmacological Center, University of Marburg, 35043 Marburg, Germany
1 shared publication - Kristin Rattay
Division of Developmental Immunology, German Cancer Research Center, Heidelberg, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
The Role of Viral Infections in the Onset of Autoimmune Diseases
Autoimmune diseases (AIDs) are the consequence of a breach in immune tolerance, leading to the inability to sufficiently differentiate between self and non-self. Immune reactions that are targeted towards self-antigens can ultimately lead to the destruction of the host’s cells and the development of autoimmune diseases. Although autoimmune disorders are comparatively rare, the worldwide incidence and prevalence is increasing, and they have major adverse implications for mortality and morbidity. Genetic and environmental factors are thought to be the major factors contributing to the development of autoimmunity. Viral infections are one of the environmental triggers that can lead to autoimmunity. Current research suggests that several mechanisms, such as molecular mimicry, epitope spreading, and bystander activation, can cause viral-induced autoimmunity. Here we describe the latest insights into the pathomechanisms of viral-induced autoimmune diseases and discuss recent findings on COVID-19 infections and the development of AIDs.
Top Cited PapersOpen AccessThe Role of Viral Infections in the Onset of Autoimmune Diseases
Autoimmune diseases (AIDs) are the consequence of a breach in immune tolerance, leading to the inability to sufficiently differentiate between self and non-self. Immune reactions that are targeted towards self-antigens can ultimately lead to the destruction of the host’s cells and the development of autoimmune diseases. Although autoimmune disorders are comparatively rare, the worldwide incidence and prevalence is increasing, and they have major adverse implications for mortality and morbidity. Genetic and environmental factors are thought to be the major factors contributing to the development of autoimmunity. Viral infections are one of the environmental triggers that can lead to autoimmunity. Current research suggests that several mechanisms, such as molecular mimicry, epitope spreading, and bystander activation, can cause viral-induced autoimmunity. Here we describe the latest insights into the pathomechanisms of viral-induced autoimmune diseases and discuss recent findings on COVID-19 infections and the development of AIDs.
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 2273000
Protective Effect of Kaempferol and Its Nanoparticles on 5‐Fluorouracil‐Induced Cardiotoxicity in Rats
Background. Fluorouracil (5‐FU) is the third most common chemotherapeutic agent used in the treatment of solid tumors. 5‐FU‐associated cardiotoxicity ranks the second causes of cardiotoxicity induced by chemotherapeutic drugs after anthracyclines. Kaempferol (KPF), a common flavonoid, possessing anti‐inflammatory, antiapoptotic, antioxidative properties, and its protective effects on cardiovascular disease has been reported in various studies. The current study is aimed at appraising the effect of KPF and KPF nanoparticles (NPs) on 5‐FU‐induced cardiotoxicity in rats. Methods. Thirty Male Wistar rats were divided into five groups as follows: control, 5‐FU, 5‐FU+10 mg/kg vitamin C, 5‐FU+ 1 mg/kg KPF, and 5‐FU+ 1 mg/kg KPF‐NPs. Cardiotoxicity was induced with an intraperitoneal injection of a single dose of 5‐FU (100 mg/kg). The control group received normal saline, and the treatment groups received KPF and KPF‐NPs with an intraperitoneal injection for 14 days. Each heart histopathological lesions were given a score of 0 to 3 in compliance with the articles for statistical analysis. Results. 5‐FU resulted in a significant cardiotoxicity represented by an increase in cardiac enzymes, MDA (malondialdehyde) levels, COX‐2 (cyclooxygenase‐2) expression, and histopathological degenerations. 5‐FU treatment also decreased body weight, TAC (total antioxidant capacity) values, VEGF (vascular endothelial growth factor) expression, blood cells, and hemoglobin (Hb) levels. Treatment with KPF and KPF‐NPs reduced oxidative stress, cardiac enzymes, COX‐2 expression, and VEGF expression. The number of blood cells, Hb levels, and histopathological degenerations, in cardiac tissue also body weight of animals, increased, followed by treatment with KPF and KPF‐NPs. Conclusion. Our results demonstrated that treatment with KPF and KPF‐NPs significantly improved cardiotoxicity induced by 5‐FU in rats.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 2273000
Open AccessProtective Effect of Kaempferol and Its Nanoparticles on 5‐Fluorouracil‐Induced Cardiotoxicity in Rats
Background. Fluorouracil (5‐FU) is the third most common chemotherapeutic agent used in the treatment of solid tumors. 5‐FU‐associated cardiotoxicity ranks the second causes of cardiotoxicity induced by chemotherapeutic drugs after anthracyclines. Kaempferol (KPF), a common flavonoid, possessing anti‐inflammatory, antiapoptotic, antioxidative properties, and its protective effects on cardiovascular disease has been reported in various studies. The current study is aimed at appraising the effect of KPF and KPF nanoparticles (NPs) on 5‐FU‐induced cardiotoxicity in rats. Methods. Thirty Male Wistar rats were divided into five groups as follows: control, 5‐FU, 5‐FU+10 mg/kg vitamin C, 5‐FU+ 1 mg/kg KPF, and 5‐FU+ 1 mg/kg KPF‐NPs. Cardiotoxicity was induced with an intraperitoneal injection of a single dose of 5‐FU (100 mg/kg). The control group received normal saline, and the treatment groups received KPF and KPF‐NPs with an intraperitoneal injection for 14 days. Each heart histopathological lesions were given a score of 0 to 3 in compliance with the articles for statistical analysis. Results. 5‐FU resulted in a significant cardiotoxicity represented by an increase in cardiac enzymes, MDA (malondialdehyde) levels, COX‐2 (cyclooxygenase‐2) expression, and histopathological degenerations. 5‐FU treatment also decreased body weight, TAC (total antioxidant capacity) values, VEGF (vascular endothelial growth factor) expression, blood cells, and hemoglobin (Hb) levels. Treatment with KPF and KPF‐NPs reduced oxidative stress, cardiac enzymes, COX‐2 expression, and VEGF expression. The number of blood cells, Hb levels, and histopathological degenerations, in cardiac tissue also body weight of animals, increased, followed by treatment with KPF and KPF‐NPs. Conclusion. Our results demonstrated that treatment with KPF and KPF‐NPs significantly improved cardiotoxicity induced by 5‐FU in rats.